The Absolute Effect / Oncology Evidence / Evidence Index
FIGHT-203
In FGFR1-rearranged myeloid/lymphoid neoplasms, can pemigatinib induce complete responses and complete cytogenetic responses?
Registry: NCT03011372 · Evidence reviewed 9 November 2026 · Aliases and follow-up publications consolidated.
Phase II open-label single-arm; 47 treated, 45 efficacy-evaluable.Primary-source evidence summaryStudy design, population and eligibility
Phase II open-label single-arm; 47 treated, 45 efficacy-evaluable.
Myeloid/lymphoid neoplasms with FGFR1 rearrangement; chronic and blast phase included.
Treatment and comparator
Intervention: Pemigatinib 13.5 mg daily (2 weeks on/1 week off or continuous).
Comparator: No concurrent control.
Endpoints
Complete response rate primary.
Key efficacy and clinical outcomes
Central-review CR 74% overall (31/42), 96% chronic phase and 44% blast phase; complete cytogenetic response 73%.
Source-reported outcome visualization
Values are reproduced from the cited report; bars are scaled within this figure. FGFR1-rearranged myeloid/lymphoid neoplasms
Median survival and hazard ratios are not fixed-time event risks; NNT is not inferred from them.
Toxicity and treatment burden
Hyperphosphataemia 76%; grade ≥3 stomatitis 19%, anaemia 15%.
Absolute effect and NNT/NNH
Rare-disease single-arm evidence; transplant eligibility and chronic vs blast phase are central to interpretation.
NNT/NNH is not calculated unless a directly reported, comparable fixed-time risk difference supports it. Median survival and hazard ratios alone do not provide an NNT.
Critical interpretation and limitations
Rare-disease single-arm evidence; transplant eligibility and chronic vs blast phase are central to interpretation.
This page is an evidence summary, not a substitute for multidisciplinary assessment or patient-specific decision-making.
Current-practice context
Review date: 9 November 2026. Primary publication and selected follow-up sources were reviewed. Full disease-specific guideline, regulatory-label and sequencing audit remains pending; verify current local recommendations and biomarker eligibility before clinical application.